# US 10,765,881 B2 · Magnetic particle conjugates and methods of activating cell signaling

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,765,881 B2
- Document ID: US10765881B2
- Status: Granted
- Kind: B2
- Application number: 16/061,848
- Filed: 2017-01-05
- Published: 2018-12-13
- Granted: 2020-09-08
- Earliest claimed: 2016-01-08
- Assignees: University of Florida Research Foundation, Inc.
- Applicants: University of Florida Research Foundation, Inc.
- Inventors: Jon P. Dobson; Josephine Allen
- Web page: https://patentgrep.com/patent/US10765881B2

## CPC

- A61N 2/02: using magnetic fields produced by coils, including single turn loops or electromagnets (A61N2/12 takes precedence)
- A61N 2/002: {in combination with another treatment}
- A61N 2/06: using magnetic fields produced by permanent magnets (A61N2/12 takes precedence)
- C12N 15/115: Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith {; Nucleic acids binding to non-nucleic acids, e.g. aptamers}
- C12N 2310/16: Aptamers
- C12N 2310/351: Conjugate
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Embodiments of the present disclosure provide for magnetic particle conjugates, methods of making the magnetic particle conjugates, methods of using magnetic particle conjugates, and the like.

## Claims

### Claim 1

A method of activating cell signaling, comprising:
introducing a magnetic particle conjugate to a subject, wherein the magnetic particle conjugate includes a magnetic core and a nucleic acid aptamer attached to the magnetic core, wherein the aptamer has an affinity for a target cell, wherein the magnetic particle conjugate binds to the target cell, wherein the binding of the magnetic particle to the target cell does not cause activation of the specific biochemical signaling cascade in the target cell; and
subjecting the magnetic particle conjugate to a magnetic field, wherein application of the magnetic field causes an energy transfer from the magnetic field to the magnetic particle to the target cell activating a specific biochemical signaling cascade in the target cell.

### Claim 2 (depends on 1)

The method of claim 1, wherein activating cell signaling is caused by transferring energy from the magnetic field to the magnetic particle and inducing a conformational change in the target cell.

### Claim 3 (depends on 2)

The method of claim 2, wherein the target cell includes a cell surface receptor, wherein the conformational change occurs in the cell surface receptor.

### Claim 4 (depends on 2)

The method of claim 2, wherein subjecting the magnetic particle conjugate to a magnetic field where the energy transfer from the magnetic particle to the cell causes hyperthermia that induces the conformational change in the cell surface receptors.

### Claim 5 (depends on 2)

The method of claim 2, wherein the conformation change in cell surface receptor causes one of the following: apoptosis, cell division, motility, stem cell differentiation, or tissue formation.

### Claim 6 (depends on 2)

The method of claim 2, wherein the aptamer has an affinity for cell surface receptors of the target cell.

### Claim 7 (depends on 2)

The method of claim 2, wherein the nucleic acid aptamer is selected from the group consisting of aptamers targeting: transforming growth factor-β receptor, vascular endothelial growth factor receptor, bone morphogenic protein receptor, and voltage-gated, ligand-gated or mechanosensitive ion channels.

### Claim 8 (depends on 2)

The method of claim 2, wherein the magnetic core is selected from the group consisting of: γFe2O3, αFe2O3, iron sulfide, strontium ferrite, barium ferrite, and cobalt ferrite.

### Claim 9

A composition comprising: a magnetic particle conjugate having a magnetic core and a nucleic acid aptamer attached to the magnetic core, wherein the aptamer has an affinity for a target cell, wherein the magnetic core is selected from the group consisting of: iron sulfide, strontium ferrite, barium ferrite, and cobalt ferrite.

### Claim 10 (depends on 9)

The composition of claim 9, wherein the nucleic acid aptamer is selected from the group consisting of aptamers targeting: transforming growth factor-β receptor, vascular endothelial growth factor receptor, bone morphogenic protein receptor, and voltage-gated, ligand-gated or mechanosensitive ion channels.

### Claim 11

A composition comprising: a magnetic particle conjugate having a magnetic core and a nucleic acid aptamer attached to the magnetic core, wherein the aptamer has an affinity for a target cell, wherein the magnetic core is selected from the group consisting of: γFe2O3 and αFe2O3, wherein the nucleic acid aptamer is selected from the group consisting of aptamers targeting: transforming growth factor-β receptor, vascular endothelial growth factor receptor, bone morphogenic protein receptor, and voltage-gated, ligand-gated or mechanosensitive ion channels.

### Claim 12 (depends on 11)

The composition of claim 11, wherein the nucleic acid aptamer is selected from the group consisting of aptamers targeting: bone morphogenic protein receptor, and voltage-gated, ligand-gated or mechanosensitive ion channels.

### Claim 13 (depends on 1)

The method of claim 1, wherein the nucleic acid aptamer is selected from the group consisting of aptamers targeting bone morphogenic protein receptor, and voltage-gated, ligand-gated or mechanosensitive ion channels.

### Claim 14 (depends on 1)

The method of claim 1, wherein the magnetic core is selected from the group consisting of: γFe2O3 and αFe2O3.

### Claim 15 (depends on 1)

The method of claim 1, wherein the magnetic core is selected from the group consisting of: iron sulfide, strontium ferrite, barium ferrite, and cobalt ferrite.
